Nancy Porter

ORCID: 0000-0003-3548-2460
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Nausea and vomiting management
  • Pancreatic and Hepatic Oncology Research
  • Childhood Cancer Survivors' Quality of Life
  • BRCA gene mutations in cancer
  • Cancer Genomics and Diagnostics
  • Hematopoietic Stem Cell Transplantation
  • Epigenetics and DNA Methylation
  • Genetic factors in colorectal cancer
  • Hemoglobinopathies and Related Disorders
  • Multiple and Secondary Primary Cancers
  • Global Cancer Incidence and Screening
  • Pain Management and Opioid Use
  • Pathogenesis and Treatment of Hiccups
  • Anesthesia and Pain Management
  • Cancer survivorship and care
  • Colorectal and Anal Carcinomas
  • Patient-Provider Communication in Healthcare
  • Esophageal Cancer Research and Treatment
  • Lymphoma Diagnosis and Treatment
  • Telemedicine and Telehealth Implementation
  • vaccines and immunoinformatics approaches
  • Polyamine Metabolism and Applications
  • Multiple Sclerosis Research Studies
  • Cancer Risks and Factors
  • Intracranial Aneurysms: Treatment and Complications

Sidney Kimmel Comprehensive Cancer Center
2021-2022

Johns Hopkins University
2021-2022

University of Baltimore
2021

Optum (United States)
2021

Johns Hopkins Medicine
2021

Cancer Research Center
2021

CT Group Of Institutions
2016

University of South Carolina
2015-2016

Sheffield Teaching Hospitals NHS Foundation Trust
2007-2015

Leatherhead Food Research
2014

Pathogenic germline variants in the ATM gene have been associated with pancreatic cancer risk. Although genetic testing identifies these approximately 1% to 3% of unselected patients cancer, lifetime risk among individuals pathogenic has not well estimated.To estimate age-specific penetrance a variant gene.This was multicenter cohort study family registries US and Canada using pedigree data from 130 kindreds variant. Data analyses were performed January 2020 February 2021.Observational...

10.1001/jamaoncol.2021.3701 article EN JAMA Oncology 2021-09-16

Uncontrolled delayed nausea and vomiting remains a problem after high-dose preparative regimens used for autologous allogeneic hematopoietic stem cell transplants. Recently, aprepitant was approved highly moderately emetogenic chemotherapy, and, in particular, is effective decreasing emesis. To evaluate its safety efficacy the transplantation setting, we performed randomized, placebo-controlled, phase 3 trial of combination with ondansetron dexamethasone patients treated ablative regimens....

10.1016/j.bbmt.2012.07.019 article EN cc-by-nc-nd Biology of Blood and Marrow Transplantation 2012-08-01

A family history of pancreatic cancer is associated with increased risk. However, risk estimates for individuals in kindreds an aggregation (>1 relative) are imprecise because small samples sizes or potentially impacted by biases inherent retrospective data.

10.1093/jnci/djac167 article EN JNCI Journal of the National Cancer Institute 2022-08-26

To assess the diagnostic value of cerebrospinal fluid (CSF) spectrophotometry, cytology, ferritin, and D-dimer measurements in investigation suspected subarachnoid haemorrhage patients with negative or equivocal computed tomography (CT) scans.CSF specimens submitted for assessment xanthochromia were examined erythrophages using a cytospin preparation stained Wright's stain, ferritin Ciba-Corning Magic IRMA assay, D-dimers Dimertest 2 latex agglutination slide test, bilirubin by scanning...

10.1136/jcp.47.11.986 article EN Journal of Clinical Pathology 1994-11-01

The optimal management of transplantation preparative regimen-induced nausea and vomiting remains unknown. We conducted a Phase III double-blind study to determine the efficacy costs oral ondansetron versus granisetron IV PRN rescue antiemetics for prevention/control associated with high-dose chemotherapy or chemoradiotherapy prior stem cell transplantation. One hundred two patients were randomized receive either 8 mg PO every hours, 1 12 32 24 hours plus 10 dexamethasone daily during day...

10.1053/bbmt.2001.v7.pm11760147 article EN cc-by-nc-nd Biology of Blood and Marrow Transplantation 2001-11-01

One of the largest, most expensive randomized, controlled trials, National Lung Screening Trial, found that annual low-dose computed tomography (LDCT) scans led to a 20% reduction in lung cancer deaths.This study describes characteristics and program implementation barriers experienced by LDCT screening programs United States.Using mixed-methods approach, Cancer Alliance Centers Excellence were surveyed interviewed 2013. Representatives from 65 centers completed an electronic questionnaire,...

10.1188/16.cjon.52-58 article EN Clinical journal of oncology nursing 2016-01-22

Although screening rates for colorectal cancer are increasing, 22 million Americans not up-to-date with recommendations. People diabetes an important and rapidly growing group at increased risk cancer. Screening status predictors of being on largely unknown in this population.This study used logistic regression modeling data from the 2012 Behavioral Risk Factor Surveillance System to examine association between according criteria US Preventive Services Task Force adults aged 50 or older....

10.5888/pcd13.150391 article EN public-domain Preventing Chronic Disease 2016-01-29

Antenatal sickle and thalassaemia screening programmes are now established in most high prevalence areas England. Although reliably detects β-thalassaemia trait, many cases, results state that α-thalassaemia trait cannot be excluded. The detection of couples at risk a child with hydrops fetalis is one the aims national programme. We, therefore, performed polymerase chain reaction (PCR) for common gene deletions to assess usefulness this technique routine practice. Between August 2001 2002,...

10.1258/096914107781261981 article EN Journal of Medical Screening 2007-06-01

Specialist Integrated Haematological Malignancy Diagnostic Services (SIHMDS) were introduced as a standard of care within the UK National Health Service to reduce diagnostic error and improve clinical outcomes. Two broad models service delivery have become established: 'co-located' services operating from single-site 'networked' services, with geographically separated laboratories linked by common management information systems. Detailed systematic cost analysis has never been published on...

10.1136/jclinpath-2014-202624 article EN Journal of Clinical Pathology 2015-01-28

Pancreatic cancer is a lethal disease with poor 5-year survival rate. Pathogenic germline variants in the coding regions of ATM, BRCA1, and BRCA2 are found up to 4.8% pancreatic patients. Germline promoter methylation gene silencing arising from variant or through other mechanisms have been described as cause tumor suppressor inactivation.We measured level genes peripheral blood lymphocytes 655 patients using real-time PCR.No evidence any these was found. Promoter levels were minimal no...

10.1016/j.pan.2021.03.015 article EN cc-by-nc-nd Pancreatology 2021-03-28

10.1177/036215377600600224 article EN Transactional Analysis Bulletin 1976-04-01

Introduction: The clinical outcomes of relapsed and refractory acute myeloid leukemia (AML) lymphoblastic (ALL) are dismal in adults treated with conventional therapy. majority patients ALL AML who subsequently cured transplanted second remission or, occasionally, beyond complete remission. A minority patients, the range 10 to 20%, relapsed/refractory disease by an allogeneic bone marrow transplant. Objective: We retrospectively examined 137 and/or were recipients transplants (matched...

10.1016/j.bbmt.2008.12.190 article EN cc-by-nc-nd Biology of Blood and Marrow Transplantation 2009-01-23

Delayed N/V is often a major toxicity in patients undergoing ablative preparative regimens prior to HSCT. Aprepitant (APR), an NK-1 antagonist effective preventing delayed with moderate and highly emetogenic standard dose chemotherapy thus may be of value the transplant setting. However APR interacts cytochrome P450 involved bioactivation high cyclophosphamide, interfere etoposide pharmacokinetics; impact regimen related (RRT) survival post transplant. While several small Phase II studies...

10.1016/j.bbmt.2009.12.017 article EN cc-by-nc-nd Biology of Blood and Marrow Transplantation 2010-02-01

Abstract Introduction: Identifying families with an underlying inherited cancer predisposition is a major goal of prevention efforts. Mendelian risk models have been developed to better predict the associated pathogenic variant developing breast/ovarian (with BRCAPRO), and pancreatic (PANCPRO). Given that variants involving BRCA2 BRCA1 predispose all three these cancers, we joint model capture shared susceptibility. Methods: We expanded existing framework for PANCPRO BRCAPRO pancreatic,...

10.1158/1538-7445.am2021-885 article EN Cancer Research 2021-07-01
Coming Soon ...